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Abstract
Rewarming from accidental hypothermia is often complicated by hypothermia-induced cardiac dysfunction, calling
for immediate pharmacologic intervention. Studies show that although cardiac pharmacologic support is applied
when rewarming these patients, a lack of updated treatment recommendations exist. Mainly due to lack of clinical
and experimental data, neither of the international guidelines includes information about pharmacologic cardiac
support at temperatures below 30 °C. However, core temperature of accidental hypothermia patients is often
reduced below 30 °C. Few human studies exploring effects of adrenergic drugs during hypothermia have been
published, and therefore prevailing information is collected from pre-clinical studies. The most prominent finding in
these studies is an apparent depressive effect of adrenaline on cardiac function when used in doses which elevate
cardiac output during normothermia. Also noradrenaline and isoprenaline largely lacked positive cardiac effects
during hypothermia, while dopamine is a more promising drug for supporting cardiac function during rewarming.
Data and information from these studies are in support of the prevailing notion; not to use adrenergic drugs at
core temperatures below 30 °C.
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Background
Rewarming victims of accidental hypothermia is often
complicated by hypothermia-induced cardiac dysfunc-
tion. In its fulminant form this condition is described as
rewarming shock; an acute heart failure with a progres-
sive fall in cardiac output (CO) where the patient termi-
nates in a sudden and intractable fall in blood pressure
[1]. This serious complication to clinical therapy adds to
the virtually unchanged low survival rate of accidental
hypothermia over the last decades [2, 3]. Cardiac sup-
portive therapy has to be instituted during rewarming in
an attempt to prevent the imminent cardiovascular col-
lapse. Inotropic drugs, i.e. drugs that enhance force of
cardiac contraction [4] could provide such pharmaco-
logic support, but current guidelines do not support this
view. Both the American Heart Association and the
European Resuscitation Council advise against using
drugs like adrenaline below 30 °C [5, 6]. Studies investi-
gating patient treatment do however report that ino-
tropic drugs are administered during rewarming in 47–
66% of patients [7, 8]. Only about 10% of patients with
acute heart failure caused by disease or events other
than hypothermia receive the same treatment [9]. This
lack of consensus-based guidelines on cardiac inotropic
support in hypothermic patients cause confusion, even
within the British health care system [10]. Importance of
finding optimal treatment for these patients is manifest
from that survival is possible after extreme exposure to
hypothermia. Case-reports show that early resuscitation
enables survival after cooling to 13.7 °C [11] or cardiac
arrest close to 7 h [12], but mortality rate is still reported
at 30% [2]. Seeking evidence-based pharmacologic treat-
ment options, we have explored the literature for pre-
clinical and clinical studies on use of inotropic drugs
during hypothermia and rewarming, with interesting
findings. Most studies, including several from our group,
focus on adrenergic receptor agonists. The information
provided, presents a valuable insight in hypothermia-
induced changes in cardiovascular pharmacology, laying
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foundation for development of new treatment strategies
and guidelines in a patient group exposed to lethal car-
diac complications during rewarming.
Methods
The aim of this paper was to describe effects of adrener-
gic agonists during hypothermia. Relevant publications
were found through literature search, using PubMed
(Medline) and Google Scholar search engines. Experi-
mental and clinical studies included in this narrative re-
view were selected according to their relevance by the
authors, who all have a special interest in hypothermia
and pharmacology. Reference lists of included papers
were studied to discover publications that were not de-
tected through use of search engines. Additional articles
describing pathophysiology of hypothermia, treatment
guidelines and general knowledge on adrenergic agonists
and receptor function, were included for background
information.
Adrenergic receptors (Table 1)
Extracellular binding of adrenergic receptor agonists fa-
cilitates initiation of intracellular processes through G-
protein coupled signalling. In 1948, Ahlquist described
how the adrenergic receptors are divided into two main
groups [13], named α- and β-receptors. Subgroups have
later been identified and separated the receptors into α1–
2 and β1–3, which have a broad variety of effects, among
them hemodynamic. The β1-receptor is considered most
important for inotropic effect and is also more numer-
ous in the mammalian heart (75%) than β2 and β3 [14].
β1-stimulation enhances heart muscle contraction, in-
crease heart rate and enhance relaxation of myocardial
tissue [15]. The effect of β1-agonists is mediated through
stimulation of adenylyl cyclase, which elevates cyclic
AMP (cAMP). This activates protein kinase A (PKA),
which phosphorylates several proteins. Phosphorylation
of sarcolemmal L-type calcium channels gives increased
calcium influx, thus enabling contraction, while phos-
phorylation of cardiac troponin I enhances myocardial
relaxation [14]. β2-stimulation most importantly gives
vasodilation due to smooth muscle relaxation [16]. Both
α1- and α2- receptors are divided into three subgroups.
Stimulation of all α1-receptors will in general induce
smooth muscle contraction, which gives vasoconstriction
[17]. The α2-receptor subgroups have differing abilities,
among them both vasodilation and vasoconstriction
[18]. Cardiovascular effects of adrenergic stimulation are
also transmitted through dopamine receptors by direct
effect on smooth muscle, giving vasodilation mediated
by D1-like receptors and indirectly by D2-like receptors.
Several dopamine receptor subtypes are located in the
human heart, namely D1, D2, D4, and D5 [19], but stimu-
lation of these receptors does not have a pronounced ef-
fect on cardiac contractility in rats [20]. Adrenergic
receptor agonists have varying affinity for β-, α- and
dopamine-receptors and their subgroups, explaining
their distinct properties.
β1-receptor function during hypothermia
As the β1-receptor is considered most important for
providing inotropic effect in normothermic conditions
[14] studies on administering adrenergic drugs to ameli-
orate rewarming shock have also targeted this receptor.
In a study from our lab we have reported a 4-fold increase
of in vivo cardiac cAMP content during β1-receptor
stimulation at 15 °C, showing that β1-receptor function is
not depressed at low temperatures. This was confirmed by
an in vitro 9-fold increase of β1-receptor sensitivity in iso-
lated rat cardiomyocytes cooled to 15 °C [21]. Such
hypothermia-induced in vitro β1-receptor super-sensitivity
was also described in isolated heart preparations from
guinea pig [22, 23] and rabbit hearts at 22 °C [24]. Results
from intact (in vivo) animal experiments studying effects
of adrenergic receptor-ligands and -blockers indicate that
both β1- and β2-receptor function is maintained during
cooling to 28–30 °C, but that response to agonist binding
is depressed by cooling below 30 °C [25–27]. The relation-
ship between an apparent increase in β-receptor sensitivity
and decreased inotropic effect below a core temperature
Table 1 Adrenergic receptors
α-receptor β-receptor Dopamine-receptor
Subgroups α1, α2 β1, β2, β3 D1, D2, D3, D4, D5
Mechanism of action G-protein coupled receptors G-protein coupled receptors G-protein coupled receptors
Molecular effects α1: Activation of PLC, IP3 mediated intracellular
calcium increase
α2: Decreased cAMP production
Increase of cAMP, protein phosphorylation
(β1, β2, β3), intracellular calcium increase (β1)
or decrease (β2)
D1, D5: Increase of cAMP
D2, D3, D4: Decreased cAMP
production
Hemodynamic effect α1: Vasoconstriction↑
α2: Mixed (vasoconstriction or vasodilation)
β1: Heart rate↑, contractility↑
β2: Vasodilation↑
D1, D5: Vasodilation↑
D2, D3, D4:: Vasoconstriction↓
Dominant location α1: Smooth muscle




D1, D2, D3, D4, D5:
Central nervous system
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of 30 °C is uncertain. Mann [28] found excessive cAMP
levels, seen during β1-receptor stimulation in hypothermic
rats [21], to be cardiotoxic, through initiating un-
physiological increase of cytosolic calcium levels, mediated
by increased phosphorylation of L-type calcium channels
[28]. Hypothermia-induced calcium overload is also
known to take place in response to prolonged
hypothermia in rats per se [29, 30] and an additional in-
creased calcium load in response to a pharmacologic
stimulation might explain lacking effect of β1-agonists
during hypothermia. Another observed effect of
temperature reduction in rats is reduced myocardial cal-
cium sensitivity due to hypothermia-induced elevation of
PKA-mediated phosphorylation of Ser 23/24 at cardiac
troponin I [31]. Increased levels of cAMP will increase
such PKA-mediated Ser 23/24 phosphorylation and give a
negative inotropic effect. Such phosphorylation will also
enhance cardiac relaxation [32], which is normalized dur-
ing rewarming from hypothermia as diastolic function is
restored [33]. Thus, favorable or harmful effects of
β1-agonists administration in hypothermic subjects
appears associated to inotropic rather than lusitropic
properties, as hypothermia-induced cardiac dysfunction is
an isolated impairment of systolic function [1].
The aforementioned studies do however show differ-
ences in species and experimental conditions and use
several β1-receptor agonists with varying properties, in-
cluding α-receptor agonism that promotes vasoconstric-
tion. A resulting increase of systemic vascular resistance
(SVR) cause a pronounced negative effect on cardiac
function in rats during hypothermia [21, 27, 34, 35]. For
assessment of clinical properties of these drugs, it is
therefore necessary to evaluate their individual pharma-
cologic effects when used during hypothermia.
Adrenergic receptor agonists (Table 2, Fig. 1)
Adrenaline
Adrenaline will enhance cardiac contraction and heart
rate and either decrease (low-dose) or increase (high-
dose) SVR in normothermic conditions [36], conducted
by loss of β-adrenergic selectivity at low doses with in-
creasing α-stimulation at higher doses.
Adrenaline during hypothermia Pharmacodynamic ef-
fects of adrenaline do not seem to be independent of
temperature changes. Rubinstein found that doses indu-
cing vasodilation in normothermic dogs would give in-
creased SVR during hypothermia and stated that the
inotropic effect of adrenaline is reduced at 25 °C [37]. A
similar study on rats conducted in our lab, showed that
a high dose of adrenaline (1.25 μg/min) increased stroke
volume (SV) and CO in normothermic animals. When
an equal dose was administered during rewarming from
15 °C however, SV and CO were unaffected. In contrast,
a low dose (0.125 μg/min) adrenaline, which induced
vasodilation during normothermic conditions, failed to
reduce SVR or mean arterial pressure (MAP) during
rewarming, but led to an elevated CO [34]. The positive
effect of low-dose adrenaline during hypothermia has
also been reported from experiments using dogs [38].
We found the same dose–response relationship during
cooling, where 0.125 μg/min but not 1.25 μg/min
adrenaline gave positive cardiac effects during cooling to
28 °C. After rewarming, only rats that had received saline
during cooling showed pre-hypothermic hemodynamic re-
sponses to adrenaline [27]. An additional study on rats
from our lab showed that 1 μg/min of adrenaline given
during cooling caused a maintained depression of cardiac
function during rewarming [35]. These results indicate
that hypothermia has a severe impact on cardiac ino-
tropic effects mediated by the β1-receptor pathway, as
β1-adrenergic stimulation during hypothermia also has
a negative impact on inotropic effect of β1-agonists
after rewarming. The same phenomenon is also ob-
served in a feline model of hypothermia and rewarm-
ing [39, 40]. From a combined in vitro and in vivo
study in our lab, we showed that this hypothermia-
induced reduction of inotropic effect via β1-receptor
stimulation is seen in the presence of in vivo and in
vitro β1-receptor super-sensitivity. Both increased β1-
receptor binding and elevated cAMP levels were seen
during administration of β1-receptor ligands in
hypothermic conditions, as compared to normother-
mia. This study indicates that the detrimental effects
of adrenaline during hypothermia is a consequence of
adrenaline-induced increase in SVR via peripheral
vascular α-receptor stimulation [21]. Failure of low
doses of adrenaline to reduce MAP during hypothermia
[34], further implies the presence of increased α-receptor
agonism, or reduced effect of β2-receptor agonism in
hypothermia.
Altogether, the present hypothermia-induced alter-
ation of pharmacodynamic effects and an expected nar-
rowed therapeutic window of adrenaline, advocate
against the use of this drug during hypothermia. This as-
sumptions gain support by data from in vitro experi-
ments. In isolated rat hearts, both SV and CO were
depressed by adrenaline at 28 °C [41], while at 12 °C
positive inotropic effects were absent [42]. Interestingly,
Schiffmann et al. demonstrated that in normothermic
rat hearts, the presence of additionally added calcium
would potentiate the inotropic effects of adrenaline. In
the hypothermic heart however, increased calcium con-
centrations [41] mediated a depressive effect of adren-
aline on SV and CO. Thus, the negative effects of
adrenaline at low temperatures could be a consequence
of hypothermia-induced calcium overload, reported in
vitro [43], as well as in vivo [29, 30].
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Table 2 β1-receptor agonists
Adrenaline Noradrenaline Isoprenaline Dobutamine Dopamine
Species Rat, dog Cat, dog, Rat, dog, rabbit, guinea pig Dog, pig, rabbit, guinea pig Dog, pig
Dosage (in vivo) 0.4 μg/kg/min – 4.2 μg/kg/min 0.2 μg/kg/min – 5.0 μg/kg/min 5.7 ng/kg/min – 1 μg/kg (bolus) 2.0 μg/kg/min – 30 μg/kg/min 2.0 μg/kg/min – 30 μg/kg/min
Administration i.v. (in vivo studies), Retrograd
coronary perfusion
(in vitro studies)
i.v. (in vivo studies) i.v. (in vivo studies), Retrograd
coronary perfusion or in
preparation solution
(in vitro studies)
i.v. (in vivo studies), Retrograd
coronary perfusion or in
preparation solution
(in vitro studies)
i.v. (in vivo studies)
Target temperature 12 °C–28 °C 28 °C–30 °C 20 °C–28 °C 22 °C–31 °C 25 °C–30 °C
Cardiac effect (hypothermia) Elevated CO (low dose)
[27, 34, 38]. Depressed CO
(high dose) [21, 27, 34, 35, 37].
Negative inotropic effects
(in vitro) [41, 42].
Increased contractile force
[26, 45]. Depressed CO [40].
No effect on CO [50, 51].
Negative or depressed
inotropic effect (in vitro)
[52, 53].
Positive inotropic effects
(in vitro) [22, 24, 54].
Elevated CO [38, 57]. Increased
contraction velocity (in vitro)
[24].
Reduced or depressed
inotropic effect (in vitro) [56].
Elevated CO or positive
inotropic effects [57, 61, 63].



















Noradrenaline has high affinity for α-receptors in con-
cert with β1-receptor affinity. Infusion of noradrenaline
therefore leads both to vasoconstriction of arterioles and
a positive inotropic effect [44].
Noradrenaline during hypothermia Cotten et al. dem-
onstrated positive inotropic effect of noradrenaline in
both normothermic controls and hypothermic (30 °C)
dogs [26]. They further described that although this ef-
fect was positive, the inotropic effect of noradrenaline
was reduced by hypothermia [45]. In cats subjected to
moderate hypothermia and rewarming, noradrenaline
had a negative effect on CO during hypothermia. The
ability of noradrenaline to induce vasoconstriction did
however appear intact during cooling, with consistent
dose-related increase in MAP [40]. Intact α-receptor
function is also apparent during noradrenaline infusion
in humans cooled on cardiopulmonary bypass to 28–
32 °C. In these patients MAP increased significantly with
noradrenaline [46]. This can be explained by intact α1-
receptor function during a wide range of temperatures,
as demonstrated in sheep arteries where vascular re-
sponse to noradrenaline abolished first when cooling to
5 °C [47]. The sensitivity of α-receptors was even found
to be increased in human skin artery preparations cooled
to 24 °C [48].
Isoprenaline
Isoprenaline is a non-selective β-receptor agonist, lack-
ing α-agonist effect. On this background studies looking
exclusively at β-receptor stimulation often use isopren-
aline as a model drug. During normothermic conditions,
isoprenaline will increase CO and decrease SVR through
β1- and β2-receptor stimulation [49].
Isoprenaline during hypothermia Conflicting results
exist of pharmacologic effects of isoprenaline at low
temperatures, especially when comparing results ob-
tained from in vitro interventional studies of cardiac tis-
sue from different species. Lauri et al. studied in vivo
hemodynamic effects of isoprenaline before, during and
after severe hypothermia (25 °C) in dogs. Isoprenaline
had no positive inotropic effect during hypothermia, but
a significant decrease in SVR indicated at least partly in-
tact β2-receptor response to stimulation [50], also seen
in man at 28–32 °C [46]. Inotropic effects of increasing
isoprenaline doses have been investigated in our intact
rat model [51] at normothermia and during cooling to
24 °C. We reported that the dose-related positive ino-
tropic response (increase in SV and CO) to isoprenaline
at 37 °C were lost during cooling to 24 °C except for the
highest dose (20 ng/min). This alteration in response to
β-receptor stimulation also remained after rewarming as
only the highest dose of isoprenaline managed to elevate
SV above baseline [51]. In vitro studies have shown de-
pressed β1-mediated inotropic effect of isoprenaline in
rat left atrial preparations at 28 and 20 °C, compared to
at 35 °C [52]. This finding finds support in another study
reporting reduced inotropic response to both isopren-
aline and adrenaline in hypothermic rabbit atria at 23 °C
[53]. In contrast, in isolated guinea pig hearts cooled to
27 °C isoprenaline still increased the contractility param-
eter LV dp/dtmax, this was accompanied by a similar in-
crease in heart rate, also mediated by β1-receptor
stimulation [54]. Further, an experiment on isolated atria
from guinea pig showed increased inotropic effects of
isoprenaline at 25 °C [22]. Sustained ability of adrenaline
and isoprenaline to increase contraction amplitude and
rate has also been reported when cooling rabbit hearts
to 22 °C [24].
Dobutamine
Dobutamine predominantly binds to β1-receptors and
has a weak effect on β2- and α-receptors. Thus, adminis-
tering dobutamine in normothermic conditions elevates
CO [55].
Dobutamine during hypothermia The inotropic effects
of dobutamine shows temperature dependency when
tested in in vitro guinea pig trabecula. Rieg et al. [56]
therefore concluded that elevating cAMP through β1-re-
ceptor stimulation for providing inotropic support in
hypothermic hearts is not an optimal strategy. In iso-
lated rabbit hearts however, dobutamine infusion in-
creased contraction velocity at 22 °C [24]. Increased























Fig. 1 Molecular structure of adrenaline, noradrenaline, isoprenaline,
dopamine and dobutamine
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dobutamine infusion during hypothermia (30 °C) in pigs
[57]. Administering dobutamine in an intact dog model
during reperfusion following 60 min global ischemia at
28 °C also showed promising cardiac effects, with in-
creased SV during rewarming using cardio-pulmonary
bypass [38].
Dopamine
Like adrenaline, noradrenaline, isoprenaline and dobuta-
mine, dopamine is a catecholamine, giving dose-
dependent stimulation of α- and β-receptors and giving
a dose-dependent positive inotropic effect in normother-
mia [58]. Different from selective adrenergic agonists,
dopamine also exerts its inotropic and vasoactive effects
through stimulation of dopamine receptors [59].
Dopamine during hypothermia The use of dopamine
as a vasopressor is recommended in the Up To Date ac-
cidental hypothermia guidelines [60]. This is supported
by a better cardiovascular recovery in dopamine-treated
dogs, after core cooling to 25 °C and subsequent
rewarming [61]. Likewise, positive inotropic effects of
dopamine were found in pigs core cooled to 30 °C [57].
However, in pigs surface cooled to 32 °C [62] and 25 °C
[63] dopamine did not elevate CO. In the latter study,
which was conducted in our lab [63], dopamine infusion
at 25 °C gave a four-fold increase in plasma concentra-
tion compared to normothermia. In difference from
other β-adrenergic drugs, cardiovascular responses of
dopamine were restored during rewarming to 30 °C [63].
It is therefore apparent from different animal models that
dopamine supports cardiac function during rewarming,
but it is uncertain whether these positive effects are
present during hypothermia below 30 °C. Based on these
findings, dopamine is the preferred drug for giving cardiac
support during rewarming in the Northern-Norwegian
guidelines for accidental hypothermia [64].
Conclusion
Pharmacodynamics
A lack of human studies evaluating cardiovascular ef-
fects of adrenergic drugs during hypothermia exists [65].
In the meantime such information can be collected from
preclinical experimental studies. This information pro-
vide important insight on the effects of pharmacologic
interventions already applied in the hypothermic patient.
It is apparent that inotropic response to β-adrenergic
stimulation seems to be depressed during severe
hypothermia. This response is also depressed after
rewarming in animals that have received such drugs dur-
ing hypothermia [51]. In hypothermic animals, adren-
aline increases SVR [21]. Studies on dobutamine
administration indicates a positive effect, but these studies
are carried out at temperatures around 30 °C [38, 57].
Advice of the current guidelines, not to use adrenergic
drugs like adrenaline below 30 °C is supported by these
preclinical observations, but recommendations for ino-
tropic support in severe accidental hypothermic (>30 °C)
patients are needed. Dopamine does not seem to have the
same detrimental effects on cardiovascular function in se-
vere accidental hypothermia as adrenaline, even in high
plasma concentrations [63], but lack effect before patients
are rewarmed to higher temperatures.
Pharmacokinetics
Knowledge about pharmacokinetic effects of adrenergic
drugs during hypothermia is limited. However, all
pharmacokinetic processes are temperature-dependent;
including absorption, distribution and elimination
(metabolism and excretion). In general, lowered temper-
atures slow all these processes down. The time to reach
distribution equilibrium will be lengthened and metabol-
ism in the liver and active excretion in the kidneys re-
duced. Thus half-life (T1/2) of active substances is
increased at low temperatures [66]. In humans, it is
known that the cytochrome P450 enzyme system is af-
fected by hypothermia. Tortorici [67] found that this re-
sulted in a 7–22% reduced clearance per degree below
37 °C of opiates, barbiturates, benzodiazepines and
neuromuscular blockers. Hypothermia does also induce
changes in pharmacokinetics of adrenergic drugs. Re-
duced catechol-O-methyl transferase activity has there-
fore been suggested to explain a hypothermia-induced
hypersensitivity to β-adrenoceptor agonists [24]. In-
creased T1/2 of adrenaline might therefore have contrib-
uted to elevated stimulation of β-adrenoceptors in a
recent study reporting increased cAMP levels during
5 min adrenaline administration in hypothermia [21], as
the normothermic T1/2 of adrenaline is 2 min [68]. Re-
duced enzymatic breakdown of cAMP through reduced
phosphodiesterase 3 activity, or reduced extracellular re-
lease of cAMP as observed in cold fibroblasts [69],
might also have boosted adrenaline-mediated cAMP in-
crease in hypothermic hearts [21]. Hypothermia-induced
increase in T1/2 is apparent for other catecholamines. At
25 °C in anesthetised pigs, we found that dopamine infu-
sion yielded plasma concentrations 4 times higher than
during normothermia. The half-life of dopamine was
doubled at this temperature and returned to normother-
mic values first at 35 °C during rewarming [63]. The
high concentrations of dopamine were however not as-
sociated with any negative hemodynamic effects.
Apart from temperature–dependent pharmacologic
changes in ligand-receptor kinetics, changes in tem-
perature also exert significant alterations in other deter-
minants of cardiac function, which may limit the
expected pharmacologic effects achieved at normother-
mia. During cooling, studies on isolated papillary muscle
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show a positive inotropic effect of hypothermia per se
[70]. In the intact pig however, cooling induce a reduc-
tion of cardiac contractile function and SV [33]. Lewis
and colleagues showed that the inotropic effect of in-
creasing heart rate during normothermic conditions in
man, is lost at a core temperature of 33 °C [71], inde-
pendent of pharmacologic interventions. Consequently,
hypothermia-induced changes in physiology, not related
to ligand-receptor kinetics, could also be involved in al-
tered pharmacodynamics of β-adrenoceptor agonists
during hypothermic conditions. Important determinants
of blood flow, like blood viscosity, are affected already at
moderate hypothermia [72]. Thus, lack of ability of the
cold blood to increase flow may be part of the challen-
ging task to provide positive inotropic, pharmacologic
support during hypothermia. The apparent depressed
function of β1-receptor agonists to provide inotropic ef-
fect in vivo below 30 °C, might therefore be multifactor-
ial. Updated guidelines on treatment of hypothermic
patients depend on further studies exploring physio-
logical effects of hypothermia and rewarming, as well as
broader knowledge on the hypothermia-induced changes
on pharmacodynamic and pharmacokinetic effects of
drugs applied in clinical practice.
Clinical implications
Findings in the reviewed literature indicate that negative
or lacking effects of adrenergic drugs during hypothermia
appears to be of multifactorial origin. Our findings from a
majority of pre-clinical studies therefore advocate that
drugs providing adrenergic receptor agonism should be
used carefully during hypothermia and rewarming. Such
information is highly relevant in the clinical setting. Re-
ports show that pharmacological interventions are being
used to provide cardiovascular support in a large propor-
tion of patients during rewarming from accidental
hypothermia [7, 8]. Hypothermia is also used as a thera-
peutic measure. Comatose survivors of cardiac arrest are
often cooled to temperatures between 32–36 °C for cere-
bral protection [73]. More than 50% of this patient group
are in need of inotropic support to facilitate adequate cir-
culation [74]. Cooling and rewarming of patients down to,
and occasionally below 20 °C is also used for cerebral pro-
tection during procedures like aortic arch surgery [73].
Providing optimal pharmacological, cardiovascular sup-
port in hypothermic patients therefore seems essential,
both in therapeutic hypothermia, and when aiming to im-
prove a high mortality rate associated with accidental
hypothermia [2]. In pigs, dopamine appear a safe way to
provide inotropic support, but lack effect at lower temper-
atures. Further, experimental studies have explored effects
of inotropic pathways like PDE3 inhibition and calcium
sensitizing, drugs that avoid the G-protein coupled
adrenergic receptors. These experiments show promising
results [75–79] on cardiovascular function, both during
cooling and rewarming. However, information from such
pre-clinical studies should be interpreted with care, when
translated to a clinical, human setting. Aiming to provide
better treatment, we call for further studies on physiology,
therapeutic interventions and careful evaluation of ino-
tropic drugs, used in hypothermic patients.
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